• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 4. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 5. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Estrogens and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Estrane steroids Estrogens and derivatives

Professional Introduction to 11α-Hydroxyestr-4-ene-3,17-dione (CAS No. 6615-00-5)

11α-Hydroxyestr-4-ene-3,17-dione, identified by its Chemical Abstracts Service (CAS) number 6615-00-5, is a significant intermediate in the field of pharmaceutical chemistry and endocrinology. This compound belongs to the class of estrogenic steroids, exhibiting a structural framework that is closely related to natural and synthetic estrogens. Its molecular structure incorporates a hydroxyl group at the 11α position and a ketone functionality at both the 3β and 17β positions, which contribute to its unique biological activity and reactivity.

The synthesis and application of 11α-Hydroxyestr-4-ene-3,17-dione have garnered considerable attention in recent years due to its role as a precursor in the development of novel therapeutic agents. The compound’s ability to serve as a building block for more complex estrogen derivatives has made it invaluable in the design of drugs targeting estrogen receptor modulators (ERMs). These ERMs are particularly relevant in the treatment of hormone-sensitive cancers, such as breast and prostate cancer, where selective estrogen receptor modulation can either activate or block estrogen-mediated pathways.

Recent advancements in medicinal chemistry have highlighted the potential of 11α-Hydroxyestr-4-ene-3,17-dione in the development of next-generation antiestrogenic compounds. Researchers have been exploring its derivatives to enhance selectivity and reduce side effects associated with traditional estrogen therapies. For instance, modifications at the 4-position of the steroid ring have led to compounds with improved affinity for specific estrogen receptors, thereby increasing therapeutic efficacy while minimizing unwanted physiological effects.

The structural motif of 11α-Hydroxyestr-4-ene-3,17-dione also makes it a valuable tool in studying estrogen signaling pathways. Studies utilizing this compound have provided insights into the mechanisms by which estrogens exert their biological effects. Notably, research has demonstrated that the hydroxyl group at the 11α position plays a critical role in modulating the binding affinity of estrogen derivatives to both alpha and beta estrogen receptors. This has implications for designing drugs that can selectively target one receptor over the other, thereby tailoring treatment regimens to individual patient needs.

In addition to its pharmaceutical applications, 11α-Hydroxyestr-4-ene-3,17-dione has been investigated for its potential role in reproductive health. Emerging evidence suggests that this compound may influence reproductive processes by interacting with estrogen-sensitive tissues. For example, studies in animal models have shown that administration of 11α-Hydroxyestr-4-ene-3,17-dione can modulate estrous cycles and reproductive hormones, indicating its utility in developing treatments for infertility and menstrual disorders.

The synthetic pathways for 11α-Hydroxyestr-4-ene-3,17-dione have also seen significant innovation. Modern synthetic methods leverage catalytic processes and biocatalysis to improve yield and purity while reducing environmental impact. These advancements align with global efforts to promote green chemistry principles in pharmaceutical manufacturing. The use of chiral auxiliaries and asymmetric catalysis has enabled the production of enantiomerically pure forms of this compound, which is crucial for achieving high selectivity in drug development.

From a regulatory perspective, 11α-Hydroxyestr-4-ene-3,17-dione (CAS No. 6615-00-5) is subject to standard guidelines for chemical substances used in pharmaceutical research and development. Compliance with Good Manufacturing Practices (GMP) ensures that the compound is produced under controlled conditions to maintain consistency and safety. Furthermore, ongoing research into its pharmacokinetic properties helps inform dosing strategies and formulation design for future drug candidates derived from this intermediate.

The future prospects for 11α-Hydroxyestr-4-ene-3,17-dione are promising, with ongoing studies exploring its potential in various therapeutic areas. Innovations in drug design are expected to expand its applications beyond traditional estrogen-related disorders into fields such as osteoporosis treatment and neuroprotection. As our understanding of steroid biochemistry evolves, so too will the roles played by intermediates like 11α-Hydroxyestr-4-ene-3,17-dione in advancing medical science.

In conclusion,11α-Hydroxyestr-4ienee--e--eee--eee--eee--eee--eee--eee--eee--eee--eee--eee--eee--eeeee---e---e---e---e---e---e---e---e---e---e---e---e---eeeee-------ee-------ee-------ee-------ee-------ee-------ee-------ee-------ee-------ee-------ee-------ee------6615-e------6615-e------6615-e------6615-e------6615-e------6615-e------6615-e------6615-e------6615-e------6615-e------6615-e------6615-e------

• 566-19-8(7-Keto-dehydroepiandrosterone)
• 604-09-1(17b-Hydroxyprogesterone)
• 57-85-2(Testosterone propionate)
• 68-96-2(Hydroxyprogesterone)
• 50-22-6(Corticosterone)
• 434-22-0(Nandrolone)
• 58-18-4(Methyltestosterone)
• 1449-05-4(18α-Glycyrrhetinic acid)
• 471-53-4(Glycyrrhetinic Acid)
• 52-39-1(Aldosterone)